Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ranibizumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    175 result(s) found for: Ranibizumab. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2020-004427-16 Sponsor Protocol Number: GR40549 Start Date*: 2021-09-28
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIO...
    Medical condition: Neovascular Age-Related Macular Degeneration (nAMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022616-39 Sponsor Protocol Number: CRFB002DGB14 Start Date*: 2010-11-30
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb ...
    Medical condition: Diabetic Macular Oedema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006760-28 Sponsor Protocol Number: 13 Start Date*: 2008-02-21
    Sponsor Name:Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie
    Full Title: Comparision of Ranibizumab (Lucentis) Monotherapy versus Combination of Ranibizumab (Lucentis) with Photodynamic Therapy (Verteporfin) in Patients with Subfoveal Choroidal Neovascularisation due to...
    Medical condition: neovascular Age-related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001970-41 Sponsor Protocol Number: 0504-19 Start Date*: 2022-03-18
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age-Related Macular De...
    Medical condition: Neovascular (Wet) Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019795-74 Sponsor Protocol Number: CRFB002D2304 Start Date*: 2010-10-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs. 0.5 mg ranibi...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) FR (Completed) ES (Completed) HU (Completed) IT (Completed) IE (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008720-33 Sponsor Protocol Number: PDP007 Start Date*: 2009-06-08
    Sponsor Name:Cliniques Universitaires St Luc
    Full Title: A one year, open, prospective study on the role of quarterly intravitreal injections of Lucentis 0,5 mg (ranibizumab) in preventing of delaying progression of radiation retinopathy in eyes treated ...
    Medical condition: Radiation retinopathy in eyes treated with Iodine 125 plaque radiotherapy for posterior uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064714 Radiation retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001047-21 Sponsor Protocol Number: 690110 Start Date*: 2014-06-09
    Sponsor Name:Sankt Eriks Eye Hospital
    Full Title: Randomized trial comparing injection frequency between Aflibercept and Ranibizumab in patients with Central Retinal Vein Occlusion with a treat and extent algorithm
    Medical condition: Central retinal vein occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007319-33 Sponsor Protocol Number: OP08/8679 Start Date*: 2009-02-19
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: Do genes predict response to treatment in age-related macular degeneration?
    Medical condition: Choroidal neovascularisation secondary to age-related macular degeneration (ARMD)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002859-34 Sponsor Protocol Number: CRFB002E2402 Start Date*: 2012-04-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen w...
    Medical condition: visual impairment due to macular edema secondary to branch retinal occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10025415 Macular oedema PT
    14.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    14.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) SE (Completed) HU (Completed) CZ (Completed) ES (Completed) SK (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) FR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003041-10 Sponsor Protocol Number: CRFB002H2301 Start Date*: 2015-04-14
    Sponsor Name:NOVARTIS FARMA S.p.A.
    Full Title: RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematu...
    Medical condition: Retinopathy of prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) EE (Completed) LT (Completed) HU (Completed) BE (Completed) AT (Completed) DE (Completed) GB (Completed) HR (Completed) FR (Completed) SK (Completed) CZ (Completed) GR (Completed) DK (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001313-20 Sponsor Protocol Number: WR42221 Start Date*: 2021-10-21
    Sponsor Name:F. Hoffman-La Roche Ltd
    Full Title: A PHASE IIIb, GLOBAL, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR−MASKED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB I...
    Medical condition: Neovascular age-related macular degeneration (nAMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003352-20 Sponsor Protocol Number: 469055 Start Date*: 2016-07-18
    Sponsor Name:University Medical Center of Johannes -Gutenberg University Mainz
    Full Title: Correlation of functional and structural outcomes with serum antibody profiles in patients with neovascular age-related macular degeneration treated with ranibizumab and healthy subjects: a prospec...
    Medical condition: Neovascular age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005091-17 Sponsor Protocol Number: 26285/13 Start Date*: 2014-02-05
    Sponsor Name:POLICLINICO GEMELLI
    Full Title: Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naïve patients WIth Neovascular age-related macular degeneration: pilot Study. –
    Medical condition: Wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006879-71 Sponsor Protocol Number: HSP01-2008 Start Date*: 2009-05-12
    Sponsor Name:HOSPITAL SAN PEDRO
    Full Title: Tratamiento del edema de macula diabético clinicamente significativo con Ranibizumab (LUCENTIS) intravitreo. TREATMENT OF DIABETIC CLINICALLY SIGNIFICANT MACULAR EDEMA WITH INTRAVITREOUS RANIBIZUMA...
    Medical condition: Edema de macula diabético refractario.REFRACTORY MACULAR EDEMA IN DIABETIC PATIENTS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001182-27 Sponsor Protocol Number: CRFB002ADE27 Start Date*: 2014-08-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001639-35 Sponsor Protocol Number: CRFB002DDE25 Start Date*: 2014-08-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to diabetic macula edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005417-38 Sponsor Protocol Number: CRFB002G2301 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) LV (Completed) PT (Completed) HU (Completed) CZ (Completed) ES (Completed) LT (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001020-38 Sponsor Protocol Number: CRFB002EDE18 Start Date*: 2011-06-24
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp...
    Medical condition: visual impairment due to macular edema following central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001019-30 Sponsor Protocol Number: CRFB002EDE17 Start Date*: 2011-06-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp...
    Medical condition: visual impairment due to macular edema following branch retinal vein occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004877-24 Sponsor Protocol Number: RFB002D2301 Start Date*: 2008-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed) HU (Completed) BE (Completed) IT (Completed) NL (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 11:30:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA